Stimulating re-epithelialization after photorefractive keratectomy

J Refract Surg. 1999 Mar-Apr;15(2 Suppl):S234-7. doi: 10.3928/1081-597X-19990302-19.

Abstract

Background: Re-epithelialization is usually complete in eyes 3 to 4 days following photorefractive keratectomy (PRK). However, this process is delayed in 0.5% of these eyes, leading to early development of haze. The authors investigated a method to stimulate re-epithelialization following PRK.

Methods: PRK was performed with the Nidek EC-5000 excimer laser. Following surgery, express-cytokinotherapy was applied. This method consisted of a single subconjunctival injection of 2.5 to 3.0 ml of ex juvanticus mixture of autoblood and immunomodulator Poludan. This mixture was then applied topically 4 times a day until re-epithelialization was complete. Poludan is an interferon inducer (complex polyA: polyU), stimulates expressed production of interferon and interleukin-2, and increases natural cytotoxicity.

Results: Thirty eyes of 30 patients with delayed re-epithelialization were treated with the described method. The average time to re-epithelialization was 7.00 + 0.64 days. Total epithelialization was complete on day 3 + 0.38 after beginning the cytokinotherapy (P < .05). Early haze developed in only 2 patients from this group. Occurrence of early haze in the control group of patients who had persistent epithelial defects 8 to 16 days postoperatively and were given traditional therapy--including corticosteroid and non-steroidal drugs--was reliably higher: 8 to 10 days (P < .01).

Conclusion: Local express-cytokinotherapy appears to be an effective method to promote quick and complete epithelialization in eyes following PRK that experience delayed re-epithelialization. This treatment may be an important part of the prevention of early haze development and achievement of better visual acuity.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Blood*
  • Epithelial Cells / physiology
  • Epithelium, Corneal / drug effects*
  • Follow-Up Studies
  • Humans
  • Hyperopia / surgery
  • Interferon Inducers / therapeutic use*
  • Lasers, Excimer
  • Middle Aged
  • Myopia / surgery
  • Photorefractive Keratectomy*
  • Polyribonucleotides / therapeutic use*
  • Reproducibility of Results
  • Treatment Outcome
  • Visual Acuity
  • Wound Healing / drug effects*

Substances

  • Interferon Inducers
  • Polyribonucleotides
  • poludan